Clinical Trials Logo
  1. Home
  2. Meningioma
  3. NCT06014905

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Meningioma Clinical Trial

Official title:
Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Clinical Trial Summary

This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior

Clinical Trial Description

Primary Objective: I. To assess the feasibility of hyperpolarized 13C MR imaging as a new and unique tool in the characterization of aggressive tumor behavior in participants with meningioma. Secondary Objectives: I. To define the most appropriate parameters for obtaining hyperpolarized 13C data from meningioma patients with a run-in study to optimize spatial and temporal resolution and coverage by detecting signal amplitudes and time dynamics. II. To measure tumor pyruvate-to-lactate, pyruvate-to-alanine, and pyruvate-to-bicarbonate conversion by 13C pyruvate MR imaging in participants with meningioma planning to undergo surgical resection within 4 weeks, using parameters. Outline: Participants will receive a single imaging procedure using HP 13C pyruvate. Participants will then be followed-up for 30 days after completion of the study or until voluntary withdrawal or death. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06014905
Study type Interventional
Source University of California, San Francisco
Contact Wendy Ma
Phone (415) 514-4418
Email Wendy.Ma@ucsf.edu
Status Recruiting
Phase Phase 1
Start date September 1, 2023
Completion date September 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Recruiting NCT03631953 - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Completed NCT01811524 - The Etiology and Progression of Brain Tumors N/A
Completed NCT03648034 - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality N/A
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Not yet recruiting NCT04386642 - Tranexamic Acid Reduce Blood Loss in Meningioma Resection Phase 4
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Active, not recruiting NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Phase 3
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Not yet recruiting NCT02978677 - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas N/A
Active, not recruiting NCT02933736 - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Early Phase 1
Completed NCT02267928 - Information Presentation Formats N/A
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Active, not recruiting NCT03071874 - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Phase 2
Recruiting NCT05416567 - Embolization for Meningioma N/A
Recruiting NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Phase 1/Phase 2